The Valley of Death in anticancer drug development: A reassessment

Trends in Pharmacological Sciences

Volumn 33, Issue 4, 2012, Pages 173-180

  Adams, David J ^a  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CRIZOTINIB; CYTARABINE; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GIRENTUXIMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IRINOTECAN; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; OLAPARIB; RUBITECAN; TOPOTECAN; VEMURAFENIB;

APOPTOSIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL SURVIVAL; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; DRUG POTENTIATION; DRUG QUALITY; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; ENZYME INHIBITION; FEASIBILITY STUDY; HUMAN; HYPOXIA; IC 50; KIDNEY ADENOMA; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 84859438323     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.02.001     Document Type: Review

References (117)

1. F. Pammolli The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
2. W.N. Hait Anticancer drug development: the grand challenges Nat. Rev. Drug Discov. 9 2010 253 254
3. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. M. Wehling Opinion. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8 2009 541 546
5. FasterCures (2011) Crossing Over the Valley of Death, FasterCures/The Center for Accelerating Medical Solutions. http://www.fastercures.org/documents/ file/Valley%20of%20Death%20-%20Translational%20Research(1).pdf
6. D. Butler Translational research: crossing the valley of death Nature 453 2008 840 842
7. B.S. Coller, and R.M. Califf Traversing the Valley of Death: a guide to assessing prospects for translational success Sci. Transl. Med. 1 2009 1 5
8. K.E. Friedl Overcoming the 'valley of death': Mouse models to accelerate translational research Diabetes Technol. Ther. 8 2006 413 414
9. J.C. Reed NCATS could mitigate pharma Valley of Death Genet. Eng. Biotechnol. News 31 2011 6 8
10. C. Leaf Why we're losing the war on cancer and how to win it Fortune 149 2004 76
11. Kolata, G. (2009) Advances elusive in the drive to cure cancer. New York Times 24 April
12. S. Begley, and M. Carmichael Desperately seeking cures Newsweek 155 2010 38 42
13. S. Begley We fought cancer. and cancer won Newsweek 152 2008 42 66
14. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
15. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat. Rev. Cancer 11 2011 393 410
16. K.R. Atkuri, and L.A. Herzenberg Culturing at atmospheric oxygen levels impacts lymphocyte function Proc. Natl. Acad. Sci. U.S.A. 102 2005 3756 3759
17. Z. Ivanovic Hypoxia or in situ normoxia: the stem cell paradigm J. Cell. Physiol. 219 2009 271 275
18. 2 histography Antioxid. Redox Signal. 9 2007 1221 1235
19. M. Stubbs Understanding the tumor metabolic phenotype in the genomic era Curr. Mol. Med. 3 2003 49 59
20. M. Stubbs, and J.R. Griffiths The altered metabolism of tumors: HIF-1 and its role in the Warburg effect Advances in Enzyme Regulation 50 2010 44 55
21. M. Puppo Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1 alpha and -2 alpha Mol. Cancer Ther. 7 2008 1974 1984
22. J.J. O'Leary Antiangiogenic effects of camptothecin analogues 9-amino-20(S)camptothecin, topotecan, and CPT-11 studied in the mouse cornea model Clin. Cancer Res. 5 1999 181 187
23. H. Kamiyama Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells J. Cancer Res. Clin. Oncol. 131 2005 205 213
24. E. Pencreach Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1 alpha axis Clin. Cancer Res. 15 2009 1297 1307
25. M.D. Cordero Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs Anti-Cancer Drugs 21 2010 932 944
26. Y. Li Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms Anti-Cancer Drugs 20 2009 770 778
27. M. Timur The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line Acta Biochim. Pol. 52 2005 897 902
28. S. Simizu Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs J. Biol. Chem. 273 1998 26900 26907
29. P. Eliasson, and J.I. Jonsson The hematopoietic stem cell niche: low in oxygen but a nice place to be J. Cell. Physiol. 222 2010 17 22
30. D.J. Adams Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient Cancer Chemother. Pharmacol. 57 2006 145 154
31. L.E. Gerweck, and K. Seetharaman Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer Cancer Res. 56 1996 1194 1198
32. L.E. Gerweck Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics Mol. Cancer Ther. 5 2006 1275 1279
33. P.M.J. McSheehy Role of pH in tumor-trapping of the anticancer drug 5-fluorouracil Adv. Enzyme Regul. 40 2000 63 80
34. N. Raghunand Enhancement of chemotherapy by manipulation of tumour pH Br. J. Cancer 80 1999 1005 1011
35. N. Raghunand Tumor acidity, ion trapping and chemotherapeutics I. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents Biochem. Pharmacol. 66 2003 1219 1229
36. A. Gabr Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH Cancer Res. 57 1997 4811 4816
37. M. Stubbs Causes and consequences of acidic pH in tumors: a magnetic resonance study Adv. Enzyme Regul. 39 1999 13 30
38. D.J. Adams, and L.R. Morgan Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development Curr. Med. Chem. 18 2011 1367 1372
39. M.P. Gleeson Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discov. 10 2011 197 208
40. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 2003 192 204
41. H. Chick An investigation of the laws of disinfection J. Hyg. (Lond.) 8 1908 92 158
42. D.J. Adams In vitro pharmacodynamic assay for cancer drug development - application to crisnatol, a new DNA intercalator Cancer Res. 49 1989 6615 6620
43. N.J. Millenbaugh A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect Cancer Chemother. Pharmacol. 45 2000 265 272
44. D.J. Adams Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay - correlation with antitumor activity in vivo Cancer Res. 50 1990 3663 3669
45. D.J. Adams Antineoplastic drug screening J. Natl. Cancer Inst. 84 1992 1288 1289
46. P. New Long-term response to crisnatol mesylate in patients with glioma Invest. New Drugs 15 1997 343 352
47. T. Furukawa Clinical applications of the histoculture drug response assay Clin. Cancer Res. 1 1995 305 311
48. L.G. Harris Hedgehog signaling: networking to nurture a promalignant tumor microenvironment Molecular Cancer Research 9 2011 1165 1174
49. Oncomed Pharmaceuticals (2011) OncoMed pharmaceuticals announces FDA clearance to commence Phase 1 testing of anti-cancer stem cell therapeutic OMP-18R5. OncoMed Pharmaceuticals, Inc. http://www.oncomed.com/news/pr/press- release-2011-04-28.pdf
50. M.B. Bracken Why animal studies are often poor predictors of human reactions to exposure J.R. Soc. Med. 102 2009 120 122
51. D.J. Cheon, and S. Orsulic Mouse models of cancer Annu. Rev. Pathol.: Mech. Disease 6 2011 95 119
52. H. Olson Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
53. A. Rangarajan, and R.A. Weinberg Opinion - comparative biology of mouse versus human cells: modelling human cancer in mice Nat. Rev. Cancer 3 2003 952 959
54. C. Nardella The APL paradigm and the 'Co-Clinical Trial' project Cancer Discov. 1 2011 108 116
55. D.W. Siemann The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents Cancer Treat. Rev. 37 2011 63 74
56. W. Wolf F-19-MRS studies of fluorinated drugs in humans Adv. Drug Del. Rev. 41 2000 55 74
57. B.C. Ahn Applications of molecular imaging in drug discovery and development process Curr. Pharm. Biotechnol. 12 2011 459 468
58. S.S. Kelkar, and T.M. Reineke Theranostics: combining imaging and therapy Bioconjug. Chem. 22 2011 1879 1903
59. D.P.J. Pan Nanomedicine strategies for molecular targets with MRI and optical imaging Future Med. Chem. 2 2010 471 490
60. T. O'Sullivan Implantable semiconductor biosensor for continuous in vivo sensing of far-red fluorescent molecules Optics Express 18 2010 12513 12525
61. P. Valdastri Wireless implantable electronic platform for chronic fluorescent-based biosensors IEEE Trans. Biomed. Eng. 58 2011 1846 1854
62. C.W. Scarantino The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter Int. J. Radiat. Oncol. Biol. Phys. 72 2008 597 604
63. L. Alnaim Therapeutic drug monitoring of cancer chemotherapy J. Oncol. Pharm. Pract. 13 2007 207 221
64. T. Buclin Who is in charge of assessing therapeutic drug monitoring? The case of imatinib Lancet Oncol. 12 2011 9 11
65. D.M. Bach Therapeutic drug monitoring in cancer chemotherapy Bioanalysis 2 2010 863 879
66. W. Hryniuk, and H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J. Clin. Oncol. 2 1984 1281 1288
67. EORTC Pharmacokinetics, Metabolism Group Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines Eur. J. Cancer Clin. Oncol. 23 1987 1083 1087
68. J. Meza-Junco, and M.B. Sawyer Drug exposure: still an excellent biomarker Biomarkers Med. 3 2009 723 731
69. T. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
70. A. Dicko Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo Expert Opin. Drug Deliv. 7 2010 1329 1341
71. E.J. Feldman First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia J. Clin. Oncol. 29 2011 979 985
72. D.D. Vonhoff He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer Inst. 82 1990 96 101
73. J. Cuzick Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer J. Clin. Oncol. 29 2011 4273 4278
74. Armstrong, D. (2011) Drugmakers' returns on research fall as pipeline projects fail. Bloomberg. http://www.bloomberg.com/news/2011-11-21/drugmakers- returns-on-research-fall-as-pipeline-projects-fail.html
75. P. Workman How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development Curr. Pharm. Des. 9 2003 891 902
76. T.A. Yap Envisioning the future of early anticancer drug development Nat. Rev. Cancer 10 2010 514 525
77. M.W. Audeh Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
78. A. Tutt Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
79. K.A. Gelmon Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol. 12 2011 852 861
80. M.J. Ratain, and R.H. Glassman Biomarkers in phase I oncology trials: Signal, noise, or expensive distraction? Clin. Cancer Res. 13 2007 6545 6548
81. P.B. Gupta Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
82. +' cell subpopulations and decreases malignant traits in colorectal cancer lines Ann. Surg. Oncol. 18 2011 1797 1804
83. K.Y. Kim Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization Biochem. Biophys. Res. Commun. 413 2011 80 86
84. D.S. Lu Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells Proc. Natl. Acad. Sci. U.S.A. 108 2011 13253 13257
85. Q.L. Tang Salinomycin inhibits osteosarcoma by targeting its tumor stem cells Cancer Lett. 311 2011 113 121
86. Y. Wang Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells Med. Chem. 7 2011 106 111
87. G.N. Zhang Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells Cancer Lett. 313 2011 137 144
88. Q.M. Zhi Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer Biomed. Pharmacother. 65 2011 509 515
89. 13C NMR Biomed. 24 2011 1006 1015
90. S.K. Chitneni Molecular imaging of hypoxia J. Nucl. Med. 52 2011 165 168
91. V. Sboros, and M.X. Tang The assessment of microvascular flow and tissue perfusion using ultrasound imaging Proc. Inst. Mech. Eng. H-J. Eng. Med. 224 2010 273 290
92. K.P. Olive Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
93. K. Kim Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring J. Control. Release 146 2010 219 227
94. D. Neri, and C.T. Supuran Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discov. 10 2011 767 777
95. M. Siebels A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients World J. Urol. 29 2011 121 126
96. J. Tostain Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment Eur. J. Cancer 46 2010 3141 3148
97. S. Kummar Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies J. Clin. Oncol. 27 2009 2705 2711
98. S. Kummar Compressing drug development timelines in oncology using phase '0' trials Nature Reviews Cancer 7 2007 131 139
99. S. Kummar Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas Cancer Res. 71 2011 5626 5634
100. Editorial (2011) Upcoming battles in the war on cancer. Cancer Discov. 1, 544-546
101. R. Brennan The war on cancer: have we won the battle but lost the war? Oncotarget 1 2010 77 83
102. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J. Pharmacol. Exp. Ther. 336 2011 3 8
103. J.L. LaMattina The impact of mergers on pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 559 560
104. A. Kamb Opinion - why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6 2007 115 120
105. J. Orloff A guide to drug discovery - opinion. The future of drug development: advancing clinical trial design Nat. Rev. Drug Discov. 8 2009 949 957
106. S.H. Woolf The meaning of translational research and why it matters JAMA 299 2008 211 213
107. P. Cuatrecasas Drug discovery in jeopardy J. Clin. Invest. 116 2006 2837 2842
108. A. Kamb What's wrong with our cancer models? Nat. Rev. Drug Discov. 4 2005 161 165
109. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
110. A. Kamb At a crossroads in oncology Curr. Opin. Pharm. 10 2010 356 361
111. B.N. Roin Unpatentable drugs and the standards of patentability Texas Law Rev. 87 2009 503 570
112. P.M. LoRusso Phase 0 clinical trials: an answer to drug development stagnation? J. Clin. Oncol. 27 2009 2586 2588
113. H. Rosen, and T. Abribat The rise and rise of drug delivery Nat. Rev. Drug Discov. 4 2005 381 385
114. J.W. Yoo Bio-inspired, bioengineered and biomimetic drug delivery carriers Nat. Rev. Drug Discov. 10 2011 521 535
115. H. van den Bongard Pharmacokinetically guided administration of chemotherapeutic agents Clin. Pharmacokinet. 39 2000 345 367
116. L.D. Mayer Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 2006 1854 1863
117. L.D. Mayer, and A.S. Janoff Optimizing combination chemotherapy by controlling drug ratios Mol. Interventions 7 2007 216 223